Wind-Tunnel Investigation of Wings with Ordinary Ailerons and Full-Span External-Airfoil Flaps

Report presents an investigation carried out in the NACA 7- by 10-foot wind tunnel of an NACA 23012 airfoil equipped, first, with a full-span NACA 23012 external-airfoil flap having a chord 0.20 of the main airfoil chord and with a full-span aileron with a chord 0.12 of the main airfoil chord on the trailing edge of the main airfoil and equipped second, with a 0.30-chord full-span NACA 23012 external-airfoil flap and a 0.13-chord full-span aileron. The results are arranged in three groups, the first two of which deal with the airfoil characteristics of the two airfoil-flap combinations and with the internal-control characteristics of the airfoil-flap-aileron combinations. The third group of tests deals with several means for balancing ailerons mounted on a special large-chord NACA 23012 external-airfoil flap. The tests included an ordinary aileron, a curtained-nose balance, a frise balance, and a tab

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease. Patients were randomly assigned to receive either evacetrapib at a dose of 130 mg or matching placebo, administered daily, in addition to standard medical therapy. The primary efficacy end point was the first occurrence of any component of the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. RESULTS: At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. After 1363 of the planned 1670 primary end-point events had occurred, the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P=0.91). CONCLUSIONS: Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease. (Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998 .)

NACA Technical Reports

Report presents an investigation carried out in the NACA 7- by 10-foot wind tunnel of an NACA 23012 airfoil equipped, first, with a full-span NACA 23012 external-airfoil flap having a chord 0.20 of the main airfoil chord and with a full-span aileron with a chord 0.12 of the main airfoil chord on the trailing edge of the main airfoil and equipped second, with a 0.30-chord full-span NACA 23012 external-airfoil flap and a 0.13-chord full-span aileron. The results are arranged in three groups, the first two of which deal with the airfoil characteristics of the two airfoil-flap combinations and with the internal-control characteristics of the airfoil-flap-aileron combinations. The third group of tests deals with several means for balancing ailerons mounted on a special large-chord NACA 23012 external-airfoil flap. The tests included an ordinary aileron, a curtained-nose balance, a frise balance, and a tab